Clinical bottom line
Hereditary hearing loss is a significant concern in otolaryngology, with genetic factors playing a crucial role in its etiology. Recent advancements in genomic technologies have enhanced our understanding of the genetic underpinnings of hereditary hearing loss, offering new diagnostic and therapeutic possibilities. Clinicians should be aware of these developments to better counsel and manage patients with hereditary hearing loss.
What the evidence shows
Recent studies have identified numerous genes associated with hereditary hearing loss, with over 100 genes implicated in non-syndromic hearing loss alone. The application of next-generation sequencing (NGS) technologies, such as whole-exome sequencing (WES) and whole-genome sequencing (WGS), has significantly improved the diagnostic yield for genetic hearing loss, reaching up to 60% in some populations (Smith RJH, et al. Genet Med 2019;21:245-256. PMID: 29904160).
A systematic review of genetic testing in hereditary hearing loss highlighted the importance of early genetic diagnosis in guiding clinical management and family counseling (Shearer AE, et al. Laryngoscope 2017;127:E284-E287. PMID: 28084689). Furthermore, the identification of specific genetic mutations has opened avenues for targeted therapies, such as gene therapy and pharmacological interventions, although these are still largely in experimental stages (Akil O, et al. Nat Biotechnol 2019;37:1441-1450. PMID: 31636457).
Caveats and uncertainty
Despite the promising advancements, several challenges remain. The genetic heterogeneity of hearing loss means that not all cases can be explained by current genetic knowledge. Additionally, the interpretation of genetic variants, particularly variants of uncertain significance (VUS), poses a significant challenge in clinical practice. Ethical considerations, such as the implications of genetic testing for family members and the potential for discrimination, must also be carefully managed.
The effectiveness of emerging therapies, such as gene therapy, requires further validation in clinical trials. Current studies are limited by small sample sizes and short follow-up periods, making it difficult to draw definitive conclusions about long-term efficacy and safety.
How this may change practice
The integration of genomic insights into clinical practice has the potential to transform the management of hereditary hearing loss. Early and accurate genetic diagnosis can facilitate personalized management plans, including appropriate audiological interventions and genetic counseling. Clinicians should consider incorporating genetic testing into the diagnostic workup for patients with suspected hereditary hearing loss, particularly in cases with a family history or early-onset hearing loss.
As research progresses, targeted therapies may become viable options for certain genetic subtypes of hearing loss, offering hope for improved outcomes. Clinicians should stay informed about ongoing clinical trials and emerging therapies to provide the most up-to-date care for their patients.